DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vonicog alfa
Vonicog alfa
International Blood/Plasma News© Is Protected by Copyright Law
Vonicog Alfa
Vonicog Alfa for Severe Von Willebrand Disease
PRAC Draft Agenda of Meeting 08-11 March 2021
Draft PDCO Agenda 07-10 September 2021
Erweiterungen Und Änderungen Der ATC- Klassifikation
Evidence Review: Vonicog Alfa for the Treatment and Prevention Of
Lists of Medicinal Products for Rare Diseases in Europe*
Active Data Protection Period Register of Innovative Drugs
PDCO Minutes of the 29 May-01 June 2018 Meeting
Abstracts (PDF)
Stembook 2018.Pdf
INN Working Document 05.179 Update December 2010
Ebenefit Highlights the Drugs Listed Below Will Require Prior Authorization Through Your GE Prescription Drug Benefits
International Nonproprietary Names for Pharmaceutical Substances (INN)
(INN) for Biological and Biotechnological Substances
Product Pipeline | Factor Viii & Vwf (February 29, 2016) Name
Incorporating Patient Perspective Into Benefit-Risk Assessments
Top View
Von Willebrand Disease
New Drugs Approved in FY 2019
Current and Emerging Options for the Management of Inherited Von Willebrand Disease
Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review
HEREDITARY/ACQUIRED BLEEDING DISORDERS Von Willebrand Disease
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
(CHMP) Agenda for the Meeting on 21-24 June 2021
TAG Mail – 25 June 2020
Bedfordshire, Luton and Milton Keynes CCG High Cost Drugs
List Item Minutes of the CHMP Meeting 28-31 May 2018 (PDF/1.03
The New Landscape of Therapeutics for the Treatment of Hemophilia
CPAG Summary Report: Vonicog Alfa for the Treatment
Products for Human
Update to the Red Amber List (March 2021)
TAG Mail – 17 Dec 2020
PRAC Agenda 06-09 July 2020
Final Belgian List
List Item Applications for New Human
Nye Legemidler Som Ikke Har Markedsføringstillatelse for Legemidler Oppført På Listen Gjelder Retningslinjens Vilkår Uavhengig Av Indikasjon for Bruken
Human Von Willebrand Factor/Factor VIII Concentrates in the Management of Pediatric Patients with Von Willebrand Disease/Hemophilia A
Drugs Formulary
Vonicog Alfa
2020 Medicines in Development for Children
July-Aug 2018 Monitoring International Trends (Pdf)
Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2021 Issue One
Nhs-England-Drugs-List-V14.1.Pdf
PRAC Agenda 11-14 January 2021
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
HCPWP Feedback from CHMP
(INN) for Biological and Biotechnological Substances
VEYVONDI, in Order to Achieve a Haemostatic Plasma Level of FVIII:C
Baggrund for Medicinrådets Anbefaling Vedrørende Vonicog Alfa Som Mulig Standardbehandling Til Von Willebrand Sygdom
Joint Formulary for Hull and East Riding of Yorkshire
PRAC Draft Agenda of Meeting 13-16 January 2020
Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England V14 Changes to Version 13
Recombinant Von Willebrand Factor for Pediatric Patient with Von Willebrand Disease: First Report in Korea
Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2020 Issue Two
National Institute for Health and Care Excellence
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Pbr Excluded Drugs List
(CHMP) Agenda for the Meeting on 27-30 January 2020